AGM Presentation
Released
Released
Announcement PDF
Annual General Meeting
27 November 2024
A transformative year of clinical and commercial success
Australian Financial Year
Q2 2023/24
Q3 2023/24
Q4 2023/24
Q1 2024/25
Q2 2024/25
ASX listing
Manufacturing
validation
completed
Positive clinical
study results
Global partnership
with Aptar Pharma
Final clinical study
results confirmed
470% faster
absorption
demonstrated
TGA Special Access
Scheme
commenced
Strategic joint
venture for
telehealth platform
Clinical data
presented at
WMSM Dubai
Clinical study
recruitment
commenced
Study recruitment
and dosing
completed
TGA Authorised
Prescriber Scheme
launched
Q3 2023/24
AGM 2024
2
Investment Highlights
LTR Pharma positioned in a clear gap in the market
Expedited
path to market
Compelling pivotal
pharmacokinetic
study data
Blockbuster
market with issues
Blue chip
partners
Multiple upcoming
milestones
Repurposed drugs with novel
delivery methods can reach the
market in the US and Australia
quickly
470% faster absorption than
oral tablets
Existing PDE5
inhibitors have a high
discontinuation rate due to
poor efficacy and side effects
Aptar Pharma: Strategic Codevelopment partner - Nasdaq
listed;
Mayne Pharma: Commercial
manufacturing partner (CMO) ASX listed
Expanding product portfolio
Manufacturing Scale up
Online Prescribing
Regulatory studies / meetings
Potential partnerships/licensing
AGM 2024
3
Understanding
the Market Need
A significant healthcare
challenge affecting
relationships and
quality of life
Physical causes
‣ Heart Health
‣ Hormone Balance
‣ Metabolic Health
Psychological Impact
‣ Relationship problems
‣ Mental Wellbeing
‣ Day to day stress
‣ Medical Treatments
‣ Hair loss
‣ Weight loss
purchasing
50% Stop
PDE5 tablets
‣ Antidepressants
1
Of men over
60% 45 experience ED
2
Growing prevalence with
age impacts quality of life
Prevalence of ED with individuals with cardiovascular risk factors,
hypertension and diabetes, is reported as high as 50%
1) Carvalheira et al., "Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for
Discontinuation," Journal of Sexual Medicine, May 2012. 2) Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
AGM 2024
4
Global Market Need
ED can impact physical and psychological health
USA
China
Aus
EU
~30m
~33m
Source: Frost and Sullivan Report, The Erectile Dysfunction Medicines Market, September 2023
~150m
60.7%
of males 45y/o+
AGM 2024
5
Estimated Market size
Forecast to be US$6.0B market by 2028
$5.94B
US$6.0B
US$5.0B
US$ billions
US$4.0B
7.0% CAGR
$3.68B
US$3.0B
$2.58B
$2.76B
$2.95B
$3.38B
$3.16B
$3.61B
$3.87B
$4.15B
US$2.0B
US$1.0B
$1.11B
$1.18B
$1.27B
$1.36B
$1.45B
$1.56B
$1.67B
$1.79B
2021
2022
2023F
2024F
2025F
2026F
2027F
2028F
US$0.0B
US
ROW
Online sales expansion
Majority of ED medication is now sold through online channels
AGM 2024
6
Current treatments
Gold standard are PDE5 inhibitor tablets which have several drawbacks
Phosphodiesterase-5 (PDE5)
inhibitors are first-line treatments
Issues with PDE5 inhibitor tablets
Product
Main
Brand(s)
Time before sexual
activity for dose
Approval
Date (US)
Generic
availability
Sildenafil
Viagra
1 hour+
1998
Yes
Tadalafil
Cialis
1 hour+
2003
Yes
Vardenafil
Levitra,
Staxyn
1 hour+
2003
Yes
Avanafil
Stendra
30 minutes+
2012
No
12 mins
TGA early
access
No
Does not work
for 30-35%
of patients
Long response
time of 1 hour +
affects spontaneity
= High
discontinuation
rate
Adverse reactions
in up to 35%
of patients
AGM 2024
7
SPONTAN® The Fast-Acting Solution
Transforming ED treatment with speed and confidence
Speed Matters
Healthcare Professional Insight
Peak concentration in as little as
9 mins, 470% faster than oral tablets
Average onset: 12 mins vs 56 mins
Patients can respond in as little as 5 minutes,
well before peak concentration is reached *.
*Based on healthcare professional feedback
Less is More
Half the dose
Similar effectiveness
Better delivery consistency
Time to peak concentration
(minutes)
Tablets
Safety
Validated safety profile
No severe events
Clinically proven
0
20
40
60
AGM 2024
8
Making headlines
– all eyes on LTP
LTR Pharma engaged
positively with all tiers of
the media in FY24, including
quality, regular coverage in
industry, business, health
and top tier mediums.
Whilst a high volume of headlines
focused on the Company’s outstanding
share price growth, the story also
attracted coverage in health-focused
consumer mediums including Men’s
Health, Body + Soul, state and national
newspapers, and more. These stories
were initiated in partnership with
leading key opinion leader, Professor
Eric Chung, and clinical practitioner and
advocate, Melissa Hadley Barrett, and
the Company’s management team.
AGM 2024
9
Company History
Progressed company substantially derisking the proposition
2020 - 2021
Acquired exclusive worldwide rights to
develop, manufacture and market SPONTAN®
through a licence agreement with SDS
Establishment of the
Scientific Advisory Board
in the field of Men’s Health
Validated the US FDA’s 505(b)(2)
regulatory pathway through an
expert regulatory review
2023
Developed the
protocol for its
bioequivalence
study, and gained
ethics approval
Initial Public Offer (IPO)
Completed an oversubscribed IPO.
Listed on the ASX on 11 December
2023 and raised AU $7M.
2022
Received early acceptance
from IP Australia for our
product trademark name
“SPONTAN®”
Adopted Mayne Health
as a commercial manufacturing
partner to produce SPONTAN® to
GMP standards
Optimised delivery and commercial
development of its nasal formulation
with drug stability data from nasal
spray device developer
2024
2020 Proof of
Concept trial
results published in
2023 in The Journal
of Sexual Medicine
Completed
packaging studies
for final commercial
product ahead of
bioequivalence study
and commercial sales
Conducted crucial
derisking activities
before moving into
clinical development
Study results released
SPONTAN®'s clinical study
to support regulatory filings,
enable early Australian
market access and
preparation for licensing and
partnering discussions
Australian Early
Access Scheme
commencement
Provision of
SPONTAN® for
unmet needs
Co-development
with Aptar Pharma
Partnership for the
commercialisation of
SPONTAN in the USA
and other key
markets
Online Platform
(Q1 CY25)
Increasing access
through telehealth
AGM 2024
10
Board of Directors
Seasoned leadership driving innovation and growth in healthcare
LEE RODNE
(Executive Chairman)
▲
25 years in healthcare and tech
sectors in both public ASX and
private enterprises.
▲
Led a healthcare spin out from ASX
Fortescue Metals Group (Allied Medical,
Admedus Ltd)
▲
▲
Worked with Professor Ian Frazer on
advancing therapeutic vaccines into
clinical studies
Track record of commercializing medical
devices in Australia, North America,
Europe and Asia with significant
experience in Nasal Spray product sales.
MS MA JA MCGUIRE
(Independent Non-Executive Director)
▲
15 years of experience providing
corporate and compliance advice to
ASX-listed public companies as an
Australian-qualified lawyer.
▲
This includes working with listed
companies as a non-executive director,
general counsel, company secretary and
in private practice.
▲
Current Non-Executive Chair of ASX
listed TechGen Metals (ASX:TG1),
non-executive director of Kuniko (ASX:
KNI) and non-executive director of
Indiana Resources Limited (ASX(IDA).
DR JULIAN CHICK
(Independent Non-Executive Director)
▲
20 years experience in senior
management and board positions,
including in ASX-listed companies
Avexa Ltd, Admedus Ltd and
current Chair of Cann Group Ltd
(ASX:CAN).
▲
Over 8 years of experience in
investment banking and reviewing
healthcare and biotechnology
investment opportunities for
private equity investors and
venture capitalists.
AGM 2024
11
Global Team, Strategic US Presence
Experienced leadership across key markets
Executive Chairman | Lee Rodne
25 years in healthcare and tech sectors in both public ASX and private enterprises.
Chief Operating Officer | Peter McLennan
17 years experience in investment banking, investor relations and operations.
Chief Finance Officer | Jacques Shipper
14 years experience in Finance, Commercial Management and Controller roles.
Medical Liaison Officer | Chris Rosewarne
Experienced pharmaceutical and medical device industry leader with over 20 years
experience.
General Manager & Business Development US |Tom Riester
25 years experience in sales and management in digital health, medical device and
precision medicine.
Vice President – US Sales & Marketing | Mike Sweeting
30 years in the Pharmaceutical industry in US commercial sales and Market Access.
Vice President Operations & Clinical Development | Dr Monil Shah
20 years of Pharmaceutical and biotechnology industry experience in drug development.
Vice President, Global Regulatory Affairs | Kip Vought
25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.
Vice President – Commercial | Danny Zanardo
25 years commercial experience in the Australian and global healthcare sectors across
pharmaceuticals and medical devices.
Chief Medical Officer | Prof Geoffrey Strange
20 years experience in Pharmaceutical and medical industries as a Senior Executive
and Medical Researcher.
US TEAM
AGM 2024
12
Upcoming Milestones
Multiple value inflection points in the year ahead
Expanding
product portfolio
Manufacturing
scale up
Online
prescribing
Regulatory
studies
& meetings
Potential
partnerships &
licensing
AGM 2024
13
Share your feedback
Discover